Figure 8

The MaSC gene signature has prognostic power in specific TNBC subtypes. The DART activation score of the MaSC gene signature across the Karn579 cohort is shown using (A) the Lehmann TNBC subtype classification [26]. TNBC subtypes are represented pink for basal-like 1 (BL1), blue basal-like 2 (BL2), orange immunomodulatory (IM), grey mesenchymal (M), magenta mesenchymal stem-like (MSL), green luminal androgen receptor (LAR), and (B) centroid classification of TNBC subtypes defined by Burstein and colleagues [34], namely the ‘luminal androgen receptor (LAR)’, ‘mesenchymal (MES)’, ‘basal-like immune-suppressed (BLIS)’, and ‘basal-like immune activated (BLIA)’ groups. MaSC DART scores are shown in the y-axis. (C) Kaplan-Meier analysis of the Karn cohort stratified according to the six TNBC subtypes defined by Lehmann and colleagues [33]. Kaplan-Meier analysis of event-free survival with follow-up information is shown. (D) BL1, (E) BL2 and (F) M classified TNBCs of the Karn579 data were analysed separately and stratified according to the highest tertile of their MaSC DART score activity. DART, Denoising Algorithm based on Relevance network Topology; MaSC, mammary stem cells; TNBC, triple-negative breast cancer.